Gut Health & GI Disorders

Overview

Gastrointestinal applications represent BPC-157’s most mechanistically direct use case — the peptide was originally isolated from gastric juice (Body Protection Compound from the stomach). Its GI-protective effects are among the best-documented in the research peptide literature, though all data comes from animal models.

BPC-157 and the Gut

BPC-157 (pentadecapeptide GEPPPGKPADDAGLV) is a 15-amino-acid fragment of human gastric juice. It:

• Protects the gastric mucosa from NSAID-, alcohol-, and stress-induced ulceration in animal models
• Promotes healing of intestinal anastomoses (surgical connections) — multiple studies showing accelerated healing vs. control
• Modulates the gut-brain axis — dopamine and serotonin systems have documented BPC-157 effects, potentially relevant to functional GI disorders
• Reduces intestinal inflammation in IBD animal models (colitis, Crohn’s models)

Administration route for GI use: Oral administration of BPC-157 achieves direct mucosal contact and potentially systemic absorption. Some researchers prefer oral for GI-specific applications; subcutaneous for systemic effects.

Important limitation: All GI evidence is animal-derived. The FDA’s 2023 prohibition from 503A compounding reflects the absence of human safety data, not evidence of harm.

GLP-1 Effects on GI Motility

GLP-1 agonists (semaglutide, liraglutide, tirzepatide) significantly affect GI motility:

• Delay gastric emptying (mechanism of satiety but also gastroparesis risk)
• Increase GI transit time
• Associated with nausea, vomiting, and constipation as class effects
• Gastroparesis risk: Anesthesiologists now advise holding GLP-1 agonists before surgery due to aspiration risk from delayed gastric emptying

These are adverse GI effects in healthy guts, but the delayed gastric emptying mechanism may have therapeutic implications in specific GI conditions.

GHK-Cu — Mucosal Anti-Inflammatory

Copper peptide GHK-Cu’s anti-inflammatory gene-regulatory effects include pathways relevant to intestinal inflammation. Limited GI-specific research, but the mechanism is applicable.

Thymosin Alpha-1 — Immune-Mediated GI Conditions

For autoimmune and immune-mediated GI conditions (inflammatory bowel disease, celiac-related immune dysregulation), TA1’s T-cell regulatory effects are mechanistically relevant. No direct IBD indication, but its immunomodulatory profile is potentially relevant.

Evidence Table

Related Guides

• BPC-157 Complete Protocol Guide
• Peptide Delivery Methods